A phase 1b study of once‐weekly carfilzomib combined with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Hematology"
DOI: 10.1002/ajh.26041
Abstract: Twice‐weekly carfilzomib with lenalidomide‐dexamethasone (Rd) is an effective regimen for newly diagnosed multiple myeloma (NDMM). Here we evaluated once‐weekly carfilzomib with Rd (once‐weekly KRd) in NDMM patients. The NDMM patients were enrolled regardless of transplant… read more here.
Keywords: newly diagnosed; multiple myeloma; weekly carfilzomib; carfilzomib ... See more keywords
Convenience, satisfaction, health-related quality of life of once-weekly 70 mg/m2 vs. twice-weekly 27 mg/m2 carfilzomib (randomized A.R.R.O.W. study)
Sign Up to like & getrecommendations! Published in 2019 at "Leukemia"
DOI: 10.1038/s41375-019-0480-2
Abstract: We compared patient-reported outcomes (PROs) with once-weekly carfilzomib 70 mg/m2 (Kd70 mg/m2) vs. twice-weekly carfilzomib 27 mg/m2 (Kd27 mg/m2) plus dexamethasone in relapsed or refractory multiple myeloma (RRMM). Patient-reported convenience/satisfaction collected at Cycle 2, Day… read more here.
Keywords: satisfaction; convenience satisfaction; weekly carfilzomib; weekly kd70 ... See more keywords
A descriptive cost‐analysis of MYX.1/MCRN003, a phase 2 clinical trial evaluating high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma
Sign Up to like & getrecommendations! Published in 2021 at "European Journal of Haematology"
DOI: 10.1111/ejh.13671
Abstract: The prevalence of multiple myeloma is increasing and there is a need to evaluate escalating therapy costs (Canadian Cancer Statistics A, 2020). The MYX.1 phase II trial showed that high‐dose weekly carfilzomib, cyclophosphamide, and dexamethasone… read more here.
Keywords: trial; carfilzomib cyclophosphamide; high dose; multiple myeloma ... See more keywords